- byAdriana Villasana
- October 2, 2024
- No comments
- 1 minute read
Uruguayan biotech Xeptiva raised a $2.5M seed round led by Zentynel, a Chilean fund specialized in biotechnology. iThink VC, FEN Ventures, ND Latam, Uruguay Biotech Ventures, and Co-founder of DLocal, Sergio Fogel, also participated in the round.
Xeptiva will use the funds to continue to develop vaccines for osteoarthritis pain and atopic dermatitis in pets.
“Our goal is to increase access to effective treatments for a greater number of patients,” said Josefina Correa, Xeptiva’s CEO.
Xeptiva Therapeutics develops and produces vaccines to treat chronic inflammatory conditions in pets. The vaccines are currently in clinical trials..
Founded in 2021 at the Neurodegeneration Laboratory of the Institut Pasteur in Montevideo, Xeptiva produced its first batch of osteoarthritis vaccines in 2024.
Read more on Tekios.
Adriana Villasana
Adriana is a content marketer with a background in copywriting, SEO, and demand generation. She has worked with global clients across various industries in both the B2B and B2C sectors. She’s also a content marketing professor and holds a degree in Communication Sciences.
You May Also Like
Mercadoni Raises $9M Series A from Brazil’s Movile
- bySophia Wood
- January 3, 2018
Movile, the Brazilian mobile application giant with more than 120M monthly users invested $9M into Colombian delivery company…
Wayra Chile Invests $500K into Three Chilean Startups
- bySophia Wood
- February 8, 2018
Wayra, the investment arm of Telefonica and Movistar, the Spanish telecom giant, announced that they’d invested a total…
Chilean construction startup Ipsum raises US$1M round, led by Cemex
- bySophia Wood
- January 10, 2018
IPSUM is streamlining construction projects across Latin America. In a story originally reported by El Mercurio, this Chilean startup,…